Literature DB >> 16845228

Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats.

M Wojewódzka-Zelezniakowicz1, E Chabielska, A Mogielnicki, K Kramkowski, A Karp, A Opadczuk, T Domaniewski, M Malinowska-Zaprzałka, W Buczko.   

Abstract

This study compared the antithrombotic effect of plasma angiotensin converting enzyme inhibitors (ACE-Is): captopril (CAP), enalapril (ENA) and tissue ACE-Is: perindopril (PER), quinapril (QUIN) in experimental venous and arterial thrombosis. Normotensive Wistar rats were treated p.o. with CAP (75 mg/kg), ENA (20 mg/kg), PER (2 mg/kg) and QUIN (3 mg/kg) for 10 days. The influence of ACE-Is on coagulation and fibrinolytic systems as well as platelet function was evaluated. The hypotensive effect of ACE-Is was equal in all groups. QUIN maintained the final carotid blood flow at the highest value in comparison to PER and plasma ACE-Is. The arterial thrombus weight was reduced in PER and QUIN groups while venous thrombus weight was also reduced after CAP. Tissue and plasma ACE-Is caused the inhibition of platelet adhesion and aggregation. A reduction of fibrin generation, prolongation of prothrombin time (PT), activated partial thromboplastin time (APTT) and shortening of euglobulin clot lysis time (ECLT) were observed after PER and QUIN treatment. In conclusion, given in equipotent hypotensive doses, tissue ACE-Is exerted more pronounced antithrombotic effect than plasma ACE-Is in experimental thrombosis. The differences between tissue and plasma ACE-Is in terms of their more pronounced inhibition of experimental thrombosis may be related to the intensified activation of fibrinolysis and inhibition of coagulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845228

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  7 in total

1.  Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective Studies.

Authors:  Bakhtawar K Mahmoodi; Mary Cushman; Inger Anne Næss; Matthew A Allison; Willem J Bos; Sigrid K Brækkan; Suzanne C Cannegieter; Ron T Gansevoort; Philimon N Gona; Jens Hammerstrøm; John-Bjarne Hansen; Susan Heckbert; Anders G Holst; Susan G Lakoski; Pamela L Lutsey; JoAnn E Manson; Lisa W Martin; Kunihiro Matsushita; Karina Meijer; Kim Overvad; Eva Prescott; Marja Puurunen; Jacques E Rossouw; Yingying Sang; Marianne T Severinsen; Jur Ten Berg; Aaron R Folsom; Neil A Zakai
Journal:  Circulation       Date:  2016-11-09       Impact factor: 29.690

2.  1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.

Authors:  S Chlopicki; J Swies; A Mogielnicki; W Buczko; M Bartus; M Lomnicka; J Adamus; J Gebicki
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

3.  Captopril and lisinopril decrease acetaldehyde effects upon the prothrombin time.

Authors:  Arthur S Brecher; Rachel Dubord
Journal:  Dig Dis Sci       Date:  2007-10-12       Impact factor: 3.199

4.  Quinapril decreases antifibrinolytic and prooxidative potential of propofol in arterial thrombosis in hypertensive rats.

Authors:  Marzena Wojewodzka-Zelezniakowicz; Wioleta Kisiel; Karol Kramkowski; Anna Gromotowicz-Poplawska; Agnieszka Zakrzeska; Adrian Stankiewicz; Patrycjusz Kolodziejczyk; Janusz Szemraj; Jerzy Robert Ladny; Ewa Chabielska
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-05-11       Impact factor: 1.636

5.  Angiotensin-converting enzyme inhibitors attenuate propofol-induced pro-oxidative and antifibrinolytic effect in human endothelial cells.

Authors:  Marzena Wojewodzka-Zelezniakowicz; Anna Gromotowicz-Poplawska; Wioleta Kisiel; Emilia Konarzewska; Janusz Szemraj; Jerzy Robert Ladny; Ewa Chabielska
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2017-01       Impact factor: 1.636

6.  Anticoagulant Activity of Low-Molecular Weight Compounds from Heterometrus laoticus Scorpion Venom.

Authors:  Thien Vu Tran; Anh Ngoc Hoang; Trang Thuy Thi Nguyen; Trung Van Phung; Khoa Cuu Nguyen; Alexey V Osipov; Igor A Ivanov; Victor I Tsetlin; Yuri N Utkin
Journal:  Toxins (Basel)       Date:  2017-10-26       Impact factor: 4.546

7.  Antithrombotic Potential of Tormentil Extract in Animal Models.

Authors:  Natalia Marcinczyk; Dominika Jarmoc; Agnieszka Leszczynska; Agnieszka Zakrzeska; Karol Kramkowski; Jakub Strawa; Anna Gromotowicz-Poplawska; Ewa Chabielska; Michal Tomczyk
Journal:  Front Pharmacol       Date:  2017-08-15       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.